Delivery Order SPE2DB25D9365-SPE2DB25FUJRD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. on August 26, 2025, for the supply of Nuplazid 34 mg capsules in quantities of 30. This firm fixed-price delivery order, with an ultimate completion date of September 17, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between DLA and the Park Ridge, Illinois-based vendor. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 29, 2025, for the supply of Nuplazid (pimavanserin) 34 mg capsules in quantities of 30 units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this delivery order under a firm fixed-price contract with a ceiling value of $10,375.53. The order represents no set-aside designation and carries an ultimate completion date...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 20, 2025. The contract covers the supply of Nuplazid 34 mg capsules in quantities of 30, with a firm fixed-price structure and an ultimate completion date of September 11, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete on an...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,458.51 on July 14, 2025, for the supply of Nuplazid 34 mg capsules (30-count packages) under contract 4568809623. The award utilizes firm fixed-price pricing with no set-aside designation and is scheduled for completion by August 4, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $10,375.53 for 30 Nuplazid 34 mg capsules by the Defense Logistics Agency's Medical Supply Chain on August 7, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a continuation of pharmaceutical supply services to the Department of Defense healthcare system. The contract carries...
- The Defense Logistics Agency awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) with an ultimate completion date of September 26, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its primary location. This delivery order is issued...
- The Defense Logistics Agency issued a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count packaging. This delivery order was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, utilizing firm fixed-price pricing with no set-aside designation. The order represents a discrete fulfillment under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $10,375.53 by the Defense Logistics Agency for Nuplazid 34 mg capsules (30-count units). The contract, issued on June 3, 2025, with an ultimate completion date of June 25, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with...
- On July 1, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units). This firm fixed-price delivery order is expected to be completed by July 23, 2025, and represents a specific fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program. The vendor, a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- SPE2DB25D9365Indefinite Delivery Contract
- SPE2DB25D9365-SPE2DB25FUJRDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. for 34 mg Nuplazid capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a single line item fulfillment under DMS Pharmaceutical Group's larger indefinite delivery contract with the DLA. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as the prime contractor and has been registered in the System for Award Management since 2001. This delivery order is issued under DMS Pharmaceutical Group's substantial $499,999,999 single-award Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, which remains valid through November 2026. The broader contract enables the DLA to procure a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Nuplazid (pimavanserin) is an antipsychotic medication used in treating Parkinson's disease psychosis, reflecting the company's established role in supplying specialty pharmaceutical products to federal military healthcare systems. The company's contracting history demonstrates consistent success in competing for pharmaceutical delivery orders across diverse product categories without set-aside restrictions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/6/25 |